VOLITIONRX LTD — Director's Dealing 2022

Apr 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2022-04-07-05:00

Reporting Person: Colman Alan (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-07-05:00	Common Stock	A	2460	—	Acquired	158710	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-07-05:00	Stock Option (Right to Buy)	$3.40	A	4533	Acquired	2031-08-03-05:00	Common Stock (4533)	Direct

Footnotes

F1: On August 3, 2021, the reporting person was awarded 7,029 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 2,460 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,230 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2: On August 3, 2021, the reporting person was granted an option to purchase 12,953 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 4,533 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,266 shares and 2,267 shares on each of August 3, 2022 and August 3, 2023, respectively.